Scilex (SCLX) vs Senti Biosciences (SNTI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Senti Biosciences (SNTI) has outperformed Scilex (SCLX) over the past year, losing 8.8% versus a loss of 96.0%. Over five years, SNTI leads with a -98.2% price change compared with -99.7% for SCLX. Senti Biosciences is the larger company by market cap ($4.6 million vs $4.0 million), about 1.2 times the size.
Scilex converts more of its revenue into profit, with a net margin of -1236.4% versus -279263.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SCLX | SNTI |
|---|---|---|
| Share price | $0.5658 | $1.77 |
| Market cap | $3.98M | $4.60M |
| 1-day change | -12.95% | -36.56% |
| YTD return | -92.55% | +70.19% |
| 1-year return | -95.96% | -8.76% |
| 5-year return | -99.74% | -98.23% |
| Forward P/E | 0.78 | — |
| EPS (TTM) | $-49.70 | $-46.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $30.25M | $22.00K |
| Revenue growth (YoY) | -46.54% | — |
| Net income (latest FY) | $-374.05M | $-61.44M |
| Gross margin | 415.83% | — |
| Operating margin | -1143.71% | -312631.82% |
| Net margin | -1236.42% | -279263.64% |
| 52-week high | $14.34 | $95.04 |
| 52-week low | $0.50 | $1.71 |
| Distance from 52-week high | -96.05% | -98.14% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +662.71% |
| Average volume | 56.11K | 108.98K |
| Shares outstanding | 7.03M | 2.60M |
| Employees | 34 | 39 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SNTI has outperformed SCLX by 87.2 percentage points over the past year.
- Scilex is more profitable, keeping -1236.4 cents of every revenue dollar as net income versus -279263.6 cents for Senti Biosciences.
About Scilex
SCLX stock →Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 34 employees
About Senti Biosciences
SNTI stock →Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company's lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 39 employees
SCLX vs SNTI FAQ
Which is bigger, Scilex or Senti Biosciences?
Senti Biosciences (SNTI) is larger, with a market capitalization of $4.60M compared with $3.98M for Scilex (SCLX).
Which stock has performed better over the past year, SCLX or SNTI?
SNTI returned -8.76% over the past 12 months, compared with -95.96% for SCLX (price return, excluding dividends). Past performance does not predict future results.
Are Scilex and Senti Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.